Literature DB >> 11521806

Overexpression of the p73 gene is a novel finding in high-risk B-cell chronic lymphocytic leukemia.

U Novak1, T J Grob, G Baskaynak, U R Peters, S Aebi, D Zwahlen, M P Tschan, K A Kreuzer, E O Leibundgut, J F Cajot, A Tobler, M F Fey.   

Abstract

The p73 protein shares structural and functional similarities with the tumour-suppressor p53, but its role in neoplastic transformation is unknown. Alternative splicing leads to the expression of at least nine p73 C-terminal mRNA splice variants (alpha, beta, gamma, delta, epsilon, zeta, eta, eta1, theta). In this survey, we analyse the expression of p73 by real-time quantitative RT-PCR, its known C-terminal variants with an RT-PCR-Southern technique and by Western blot in samples of 51 patients with B-CLL, normal B lymphocytes from eight individuals, and five haematopoetic cell lines. p73alpha protein expression positively correlated with higher risk B-CLL stages (P = 0.046). Total p73 mRNA expression was higher (P = 0.01) and p73alpha protein more frequently detected (P = 0.008) in B-CLL compared with normal CD19+-B-lymphocytes. p73 C-terminal mRNA variants were expressed both in B-CLL and in normal B-lymphocytes, but their expression was biased since the gamma (P = 0.041), the theta (P < 0.001), and the eta variant (P = 0.033) prevailed in normal B-lymphocytes. In summary, we conclude that the accumulation of p73, the expression pattern of particular p73 variants and its link to progression may play a distinct role in the molecular pathology B-CLL.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11521806     DOI: 10.1023/a:1011153206003

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  10 in total

1.  Aberrant expression of DeltaNp73 in benign and malignant tumours of the prostate: correlation with Gleason score.

Authors:  M Guan; Y Chen
Journal:  J Clin Pathol       Date:  2005-11       Impact factor: 3.411

2.  TAp73alpha protects small cell lung carcinoma cells from caspase-2 induced mitochondrial mediated apoptotic cell death.

Authors:  Naveen Muppani; Ulrika Nyman; Bertrand Joseph
Journal:  Oncotarget       Date:  2011-12

3.  CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53.

Authors:  Frank Dicker; Arnon P Kater; Carlos E Prada; Tetsuya Fukuda; Januario E Castro; Guizhen Sun; Jean Y Wang; Thomas J Kipps
Journal:  Blood       Date:  2006-06-01       Impact factor: 22.113

4.  BRD4 drives esophageal squamous cell carcinoma growth by promoting RCC2 expression.

Authors:  Qiong Wu; Fangfang Liu; Mengmeng Ge; Kyle Vaughn Laster; Lixiao Wei; Ruijuan Du; Ming Jiang; Jing Zhang; Yafei Zhi; Guoguo Jin; Simin Zhao; Dong Joon Kim; Zigang Dong; Kangdong Liu
Journal:  Oncogene       Date:  2021-11-08       Impact factor: 9.867

5.  Identification of the Potential Correlation between Tumor Protein 73 and Head and Neck Squamous Cell Carcinoma.

Authors:  Yuming Chen
Journal:  Dis Markers       Date:  2022-06-15       Impact factor: 3.464

6.  The expression of p73, p21 and MDM2 proteins in gliomas.

Authors:  Makoto Kamiya; Yoichi Nakazato
Journal:  J Neurooncol       Date:  2002-09       Impact factor: 4.130

7.  Expression of p63 in anaplastic large cell lymphoma but not in classical Hodgkin's lymphoma.

Authors:  Gabriela Gualco; Lawrence M Weiss; Carlos E Bacchi
Journal:  Hum Pathol       Date:  2008-07-11       Impact factor: 3.466

8.  Interplay between TAp73 Protein and Selected Activator Protein-1 (AP-1) Family Members Promotes AP-1 Target Gene Activation and Cellular Growth.

Authors:  Deepa Subramanian; Wilawan Bunjobpol; Kanaga Sabapathy
Journal:  J Biol Chem       Date:  2015-05-27       Impact factor: 5.157

9.  Hsp72 mediates TAp73α anti-apoptotic effects in small cell lung carcinoma cells.

Authors:  Ulrika Nyman; Naveen Reddy Muppani; Boris Zhivotovsky; Bertrand Joseph
Journal:  J Cell Mol Med       Date:  2011-08       Impact factor: 5.310

10.  TAp73β-mediated suppression of cell migration requires p57Kip2 control of actin cytoskeleton dynamics.

Authors:  Johanna Rodhe; Edel Kavanagh; Bertrand Joseph
Journal:  Oncotarget       Date:  2013-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.